This is the first publication to report IHC data for tumor-nest and TME compartments in NSCLC samples using the Merck KGaA anti-PD-L1 clone MKP1A07310 for Avelumab development together with an immune panel of effector and regulatory TIL [13], as well as to show the effects of PD-L1 staining cut-off points, and the stratification of biologically relevant PD-L1 staining patterns in tumor-nest and TME compartments. The gene discussed is CD274; the disease is non-small cell lung carcinoma.